Meeting
2015 ASCO Annual Meeting
The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs).
Authors
Amelie Schramm
Universitaetsfrauenklinik Ulm, Ulm, Germany
Amelie Schramm , Thomas W. P. Friedl , Susanne Albrecht , Jens Bodo Huober , Brigitte Kathrin Rack , Elisabeth Katharina Trapp , Peter A. Fasching , Florin-Andrei Taran , Andreas D. Hartkopf , Andreas Schneeweiss , Volkmar Mueller , Bahriye Aktas , Klaus Pantel , Franziska Meier-Stiegen , Wolfgang Janni , Tanja N. Fehm
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Circulating Tumor Cells
Clinical Trial Registration Number
NCT01619111/NCT02035813/NCT02344472
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS11109)
DOI
10.1200/jco.2015.33.15_suppl.tps11109
Abstract #
TPS11109
Poster Bd #
324a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
The DETECT study concept: Individualized therapy of metastatic breast cancer.
First Author: Arkadius Polasik
Poster
2014 ASCO Annual Meeting
DETECT III/IV: Two combined clinical trials based on the phenotype of circulating tumor cells (CTCs).
First Author: Susanne Albrecht
Poster
2024 ASCO Breakthrough
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
First Author: Joohyuk Sohn
Poster
2022 ASCO Annual Meeting
A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).
First Author: Se Hyun Kim